

28 November 2018

#### PERFORMANCE RIGHTS APPROVED BY SHAREHOLDERS

Lynas Corporation Ltd (ASX:LYC, OTC:LYSDY) confirms that, during the AGM held on 27 November 2018, Shareholders approved Resolution 5 relating to a proposed award of Performance Rights. As set out in the 2018 AGM Notice, the Performance Rights that are now being awarded in accordance with Resolution 5 are as follows:

- 120,055 FY18 STI performance rights for the benefit of Amanda Lacaze, the Lynas CEO and Managing Director. This award of STI Performance Rights arose from satisfaction of performance hurdles relating to FY18. The performance hurdles that were satisfied in FY18 related to cashflow, NdPr production volume and team / individual performance. The STI Performance Rights have a 1 year vesting period. Further detail is provided in the remuneration report section of the FY18 financial report and in the 2018 AGM Notice.
- 2. 324,353 LTI Performance Rights for the benefit of Amanda Lacaze. The LTI Performance Rights have a three year vesting period and they are subject to vesting conditions relating to EBIT growth and Total Shareholder Return over the next three years. Further details are provided in the 2018 AGM Notice.

Attached is an Appendix 3B concerning the award of Performance Rights.

For all media enquiries please contact Jennifer Parker or Lauren Stutchbury from Cannings Corporate Communications on +61 2 8284 9990.

Andrew Arnold
Company Secretary



## **Appendix 3B**

# New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12

Name	of entity		
LYN	AS CORPORATION LTD		
ABN			
27 00	9 066 648		
We (the entity) give ASX the following information.			
	: <b>1 - All issues</b> ust complete the relevant sections (attac	h sheets if there is not enough space).	
1	<sup>+</sup> Class of <sup>+</sup> securities issued or to be issued	Unlisted Performance Rights	
2	Number of *securities issued or to be issued (if known) or maximum number which may be issued	444,408	
3	Principal terms of the +securities (eg, if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if	The Employee Performance Rights are subject to the Performance Conditions specified in the Lynas AGM Notice 2018 and are exercisable without further consideration on the dates specified in section 9	

+convertible

conversion)

securities,

conversion price and dates for

the

4	Do the *securities rank equally in all respects from the date of allotment with an existing *class of quoted *securities?  If the additional securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment	N/A
5	Issue price or consideration	The Performance Rights were valued at \$2.2086 per Performance Right
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	To be granted for the benefit of the CEO of the Company on the basis set out in the Lynas AGM Notice 2018
6a	Is the entity an *eligible entity that has obtained security holder approval under rule 7.1A?  If Yes, complete sections 6b – 6h in relation to the *securities the subject of this Appendix 3B, and comply with section 6i	No
6b	The date the security holder resolution under rule 7.1A was passed	
6c	Number of *securities issued without security holder approval under rule 7.1	
6d	Number of *securities issued with security holder approval under rule 7.1A	
	,	

Appendix 3B Page 2 01/08/2012

<sup>+</sup> See chapter 19 for defined terms.

6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)		
6f	Number of securities issued under an exception in rule 7.2		
	ander an exception in rule 7.2		
6g	If securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the issue date and both values. Include the source of the VWAP calculation.		
-1		Γ	
6h	If securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements		
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements		
7	Dates of entering *securities into uncertificated holdings or despatch of certificates	The Performance Rights will be granted with effect from the date of Board approval of the proposed grant of Performance Rights, being 31 August 2018	
			<del></del>
		Number	+Class
8	Number and *class of all *securities quoted on ASX (including the securities in section 2 if applicable)	665,681,660	Ordinary shares

9 Number and \*class of all \*securities not quoted on ASX (including the \*securities in section 2 if applicable)

Number	+Class
1,830,247	LTI Performance Rights exercisable for no further consideration, subject to vesting conditions, in the period 18 September 2018 to 18 September 2020
2,218,578	LTI Performance Rights exercisable for no further consideration, subject to vesting conditions, in the period 30 August 2019 to 30 August 2021
2,932,923	Strategic Performance Rights exercisable for no further consideration, subject to vesting conditions, in the first employee trading window after 28 August 2019
900,336	LTI Performance Rights exercisable for no further consideration, subject to vesting conditions, in the period 28 August 2020 to 28 August 2022
471,983	STI Performance Rights exercisable for no further consideration in the first employee trading window after 31 August 2019
690,004	LTI Performance Rights exercisable for no further consideration, subject to vesting conditions, in the period 31 August 2021 to 31 August 2023
15,242,003.79	US\$15,242,003.79 of Convertible Bonds at 1.875% p.a. maturing 30 September 2020, convertible at A\$1.00 per share based on an exchange rate of A\$1.00 = US\$0.75. Fractions of a share are rounded down on conversion.
23,256,258	Warrants exercisable at \$0.50 on or before 30 September 2020

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

N/A

Appendix 3B Page 4 01/08/2012

<sup>+</sup> See chapter 19 for defined terms.

## Part 2 - Bonus issue or pro rata issue

11	Is security holder approval required?	
12	Is the issue renounceable or non-renounceable?	
13	Ratio in which the *securities will be offered	
14	<sup>+</sup> Class of <sup>+</sup> securities to which the offer relates	
15	<sup>+</sup> Record date to determine entitlements	
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	
17	Policy for deciding entitlements in relation to fractions	
18	Names of countries in which the entity has *security holders who will not be sent new issue documents	
	Note: Security holders must be told how their entitlements are to be dealt with.	
	Cross reference: rule 7.7.	
19	Closing date for receipt of acceptances or renunciations	
20	Names of any underwriters	
	- · · · · · · · · · · · · · · · · · · ·	
21	Amount of any underwriting fee or commission	
22	Names of any brokers to the issue	
23	Fee or commission payable to the broker to the issue	

24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of *security holders	
25	If the issue is contingent on +security holders' approval, the date of the meeting	
26	Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled	
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	
28	Date rights trading will begin (if applicable)	
29	Date rights trading will end (if applicable)	
30	How do *security holders sell their entitlements <i>in full</i> through a broker?	
31	How do *security holders sell part of their entitlements through a broker and accept for the balance?	
32	How do *security holders dispose	
,	of their entitlements (except by sale through a broker)?	
33	<sup>+</sup> Despatch date	

Appendix 3B Page 6 01/08/2012

<sup>+</sup> See chapter 19 for defined terms.

### You need only complete this section if you are applying for quotation of securities Type of securities 34 (tick one) (a) Securities described in Part 1 (b) All other securities Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible Entities that have ticked box 34(a) Additional securities forming a new class of securities Tick to indicate you are providing the information or documents If the +securities are +equity securities, the names of the 20 largest holders of the 35 additional \*securities, and the number and percentage of additional \*securities held by those holders 36 If the +securities are +equity securities, a distribution schedule of the additional +securities setting out the number of holders in the categories 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over A copy of any trust deed for the additional \*securities 37 Entities that have ticked box 34(b) 38 Number of securities for which <sup>+</sup>quotation is sought Class of \*securities for which 39

Part 3 - Quotation of securities

quotation is sought

40	Do the *securities rank equally in all respects from the date of allotment with an existing *class of quoted *securities?		
	If the additional securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment		
41	Reason for request for quotation now		
	Example: In the case of restricted securities, end of restriction period		
	(if issued upon conversion of another security, clearly identify that other security)		
		Number	+Class
42	Number and *class of all *securities quoted on ASX (including the securities in clause 38)		

Appendix 3B Page 8 o1/08/2012

<sup>+</sup> See chapter 19 for defined terms.

#### **Quotation agreement**

- <sup>†</sup>Quotation of our additional <sup>†</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>†</sup>securities on any conditions it decides.
- 2 We warrant the following to ASX.
  - The issue of the \*securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those \*securities should not be granted \*quotation.
  - An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the <sup>+</sup>securities to be quoted under section 1019B of the Corporations Act at the time that we request that the <sup>+</sup>securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before †quotation of the †securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here: Date: 28 November 2018

Company Secretary)

Print name: ANDREW ARNOLD

== == == ==

01/08/2012 Appendix 3B Page 9

<sup>+</sup> See chapter 19 for defined terms.